"Tiotropium Bromide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
| Descriptor ID |
D000069447
|
| MeSH Number(s) |
D02.145.074.722.822.887 D03.132.889.601.887 D03.605.084.500.722.822.887 D03.605.869.822.887
|
| Concept/Terms |
Tiotropium Bromide- Tiotropium Bromide
- Bromide, Tiotropium
- 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane bromide
BA 679 BR- BA 679 BR
- 679 BR, BA
- BR, BA 679
- BA-679 BR
- BA679 BR
|
Below are MeSH descriptors whose meaning is more general than "Tiotropium Bromide".
Below are MeSH descriptors whose meaning is more specific than "Tiotropium Bromide".
This graph shows the total number of publications written about "Tiotropium Bromide" by people in this website by year, and whether "Tiotropium Bromide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 4 | 4 |
| 2011 | 0 | 3 | 3 |
| 2013 | 0 | 3 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tiotropium Bromide" by people in Profiles.
-
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 Apr; 202(2):119-125.
-
Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
-
Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment. Respir Med. 2021 01; 176:106278.
-
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020 Jul 09; 21(1):177.
-
Effects of baseline symptom burden on treatment response in COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:181-194.
-
Lung function trajectories and chronic obstructive pulmonary disease: current understanding and knowledge gaps. Curr Opin Pulm Med. 2018 03; 24(2):124-129.
-
Therapeutic Effects of a Long-Acting Cholinergic Receptor Blocker, Tiotropium Bromide, on Asthma. Med Sci Monit. 2018 Feb 15; 24:944-950.
-
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
-
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016 11; 120:16-24.
-
Long-acting bronchodilators in COPD: an evolving story. Lancet Respir Med. 2013 Sep; 1(7):499-501.